CH
Therapeutic Areas
Artiva Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AlloNK® + Rituximab | Refractory Rheumatoid Arthritis (RA) | Phase 1/2 |
| AlloNK® + Obinutuzumab | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1/2 |
| CAR-NK (AB-205) | CD5+ Hematologic Malignancies | Preclinical |
| CAR-NK (AB-201) | HER2+ Solid Tumors | Preclinical |
Leadership Team at Artiva Biotherapeutics
FA
Fred Aslan, M.D.
President and Chief Executive Officer
SB
Subhashis Banerjee, M.D.
Chief Medical Officer
JB
Jennifer Bush
Chief Operating Officer
TH
Thad Huston
Chief Financial Officer
BD
Benjamin Dewees
SVP, Regulatory Affairs
DM
David Moriarty, Ph.D.
SVP, Clinical Operations
HR
Heather Raymon, Ph.D.
SVP, Research & Early Development
FX
Feng Xu
SVP, Biometrics
AC
Andrew Cronauer
VP, General Counsel & Corporate Secretary
SM
Sara Mills
VP, Regulatory Affairs, CMC